Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy

Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients

(2022) Vaiva Petrenaite et al.   EPILEPSY RESEARCH

E-values for effect heterogeneity and approximations for causal interaction

(2022) Maya B Mathur et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

ABCB1, ABCG2, ABCC1, ABCC2 and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?

(2021) Henrike Bruckmueller et al.   Expert Opinion on Drug Metabolism & Toxicology

Effects of single and repetitive valproic acid administration on the gene expression of placental transporters in pregnant rats: An analysis by gestational perio

(2020) Naoko Jinno et al.   REPRODUCTIVE TOXICOLOGY

PharmGKB summary

(2020) Taraswi Mitra-Ghosh et al.   Pharmacogenetics and Genomics

Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses

(2020) Janthima Methaneethorn et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy

(2018) Iva Klarica Domjanović et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A systematic review of population pharmacokinetics of valproic acid

(2018) Janthima Methaneethorn   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Adverse placental effects of valproic acid: Studies in perfused human placentas

(2018) Miriam Rubinchik-Stern et al.   EPILEPSIA

Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines

(2018) Arne Reimers et al.   Drug Design Development and Therapy

PharmGKB summary

(2017) Alison E. Fohner et al.   Pharmacogenetics and Genomics

The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)

(2015) Kerstin Römermann et al.   NEUROPHARMACOLOGY

MatchIt: Nonparametric Preprocessing for Parametric Causal Inference

(2015) Daniel E. Ho et al.   Journal of Statistical Software

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

(2014) Oliver Bruhn et al.   Expert Opinion on Drug Metabolism & Toxicology

UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems

(2012) T Haslemo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Recommendations for presenting analyses of effect modification and interaction

(2012) Mirjam J Knol et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Association Between Lamotrigine Concentrations and ABCB1 Polymorphisms in Patients With Epilepsy

(2012) Mila Lovrić et al.   THERAPEUTIC DRUG MONITORING

Functional analysis of UGT1A4P24Tand UGT1A4L48Vvariant enzymes

(2011) Jin Zhou et al.   PHARMACOGENOMICS

Very important pharmacogene summary

(2010) Laura M. Hodges et al.   Pharmacogenetics and Genomics

A pharmacogenetics study of the human glucuronosyltransferase UGT1A4

(2009) Marie-Odile Benoit-Biancamano et al.   Pharmacogenetics and Genomics

The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane

(2007) M. Huls et al.   KIDNEY INTERNATIONAL